Extract from the Register of European Patents

EP About this file: EP0649430

EP0649430 - DERIVATIVES OF 16-MEMBERED RING ANTIBIOTIC MACROLIDES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.10.1998
Database last updated on 08.04.2026
Most recent event   Tooltip23.10.1998No opposition filed within time limitpublished on 09.12.1998 [1998/50]
Applicant(s)For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
[N/P]
Former [1995/17]For all designated states
PFIZER INC.
235 East 42nd Street
New York, N.Y. 10017 / US
Inventor(s)01 / HECKER, Scott, J.
1298 Pequot Trail
Stonington, CT 06378 / US
02 / JEFSON, Martin, R.
15 Bayview Avenue
Stonington, CT 06378 / US
03 / McFARLAND, James, W.
24-2 Burr Road
Lyme, CT 06371 / US
[1995/17]
Representative(s)Hayles, James Richard, et al
Pfizer
ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR / FR
[N/P]
Former [1995/27]Hayles, James Richard, et al
Pfizer Limited, Patents Department, Ramsgate Road
Sandwich Kent CT13 9NJ / GB
Former [1995/17]Bradbrook, Geoffrey William
PFIZER LIMITED Ramsgate Road
Sandwich Kent, CT13 9NJ / GB
Application number, filing date93914300.407.06.1993
[1995/17]
WO1993US05210
Priority number, dateUS1992091424215.07.1992         Original published format: US 914242
US1992099624323.12.1992         Original published format: US 996243
[1995/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9402496
Date:03.02.1994
Language:EN
[1994/04]
Type: A1 Application with search report 
No.:EP0649430
Date:26.04.1995
Language:EN
The application published by WIPO in one of the EPO official languages on 03.02.1994 takes the place of the publication of the European patent application.
[1995/17]
Type: B1 Patent specification 
No.:EP0649430
Date:17.12.1997
Language:EN
[1997/51]
Search report(s)International search report - published on:EP03.02.1994
ClassificationIPC:C07H17/08, A61K31/70
[1995/17]
CPC:
C07H17/08 (EP,KR,US); A61K31/7048 (KR); A61P31/04 (EP)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   NL,   PT,   SE [1997/18]
Former [1995/17]AT,  BE,  CH,  DE,  DK,  ES,  FR,  GB,  GR,  IE,  IT,  LI,  LU,  NL,  PT,  SE 
TitleGerman:DERIVATE VON 16-GLIEDRIGEN ANTIBIOTISCHEN MACROLIDEN[1995/17]
English:DERIVATIVES OF 16-MEMBERED RING ANTIBIOTIC MACROLIDES[1995/17]
French:DERIVES DE MACROLIDES ANTIBIOTIQUES A NOYAU A 16 ELEMENTS[1995/17]
Entry into regional phase16.12.1994National basic fee paid 
16.12.1994Designation fee(s) paid 
16.12.1994Examination fee paid 
Examination procedure08.12.1993Request for preliminary examination filed
International Preliminary Examining Authority: EP
16.12.1994Examination requested  [1995/17]
04.03.1996Despatch of a communication from the examining division (Time limit: M04)
25.06.1996Reply to a communication from the examining division
04.03.1997Despatch of communication of intention to grant (Approval: No)
12.05.1997Despatch of communication of intention to grant (Approval: later approval)
09.06.1997Communication of intention to grant the patent
19.08.1997Fee for grant paid
19.08.1997Fee for publishing/printing paid
Opposition(s)18.09.1998No opposition filed within time limit [1998/50]
Fees paidRenewal fee
16.03.1995Renewal fee patent year 03
27.03.1996Renewal fee patent year 04
10.04.1997Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]   CHEMICAL ABSTRACTS, vol. 102, 1985, Columbus, Ohio, US; abstract no. 185436n, '20,23-Dideoxy-20,23-bis(disubstituted amino)mikamycinosylrelonolide.' page 616 ;column 1 ; [Y]
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.